Opthea (ASX:OPT) has announced the appointment of Sujal Shah to its board of directors, effective April 4.
Opthea is a clinical‐stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age‐related macular degeneration (wet AMD).
Mr Shah will also become chair of the Audit and Risk Committee.
The company has also announced that Daniel Spiegelman has resigned from the board and as chair of the Audit and Risk Committee.
Mr Shah is an accomplished biopharmaceutical executive with extensive leadership and product development experience and a track record in capital formation.
Most recently, Mr Shah served as President and CEO of CymaBay Therapeutics, which Gilead Sciences acquired for approximately $4.3 billion in total equity value in March 2024.
"We are delighted to welcome Sujal to our Board of Directors as we rapidly advance the registrational program for sozinibercept in wet AMD and prepare for key upcoming clinical, regulatory and commercial milestones," said Jeremy Levin, chair of the Opthea board of directors.
"Sujal's significant experience driving value for biotech companies through successful product and commercial development will be an invaluable resource to the Opthea team as we enter this pivotal growth phase of the company."
"It's a privilege to join the Board of Opthea at such a transformative time," said Sujal Shah. "I look forward to partnering with the executive leadership team and the Board as we continue to drive sozinibercept forward, with the goal of enhancing vision outcomes for patients worldwide."
Dr Levin added, "On behalf of the Opthea organization, I want to express our gratitude and appreciation to Dan Spiegelman, who will now transition from our Board, for his work as a non‐Executive Director and Audit and Risk Committee Chairman. We are very grateful for Dan's contribution to the Company."
